30 closest matches · ranked by relevance
Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
Primary: Comparison of Areas Under the Curve (AUC) to the Last Time With a Concentration ≥ LLOQ [AUC0-t] and to Infinity [AUCinf] — 2,313; 2,098; 2,469; 2,175 hr x ng/mL
Rheumatoid Arthritis (RA)
Primary: Dose-Normalized AUC[0-Inf] for MTX — 109.47; 140.84; 136.45 ng*hr/mL/mg
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 281.111; 257.194 ng/mL
Healthy
Primary: Cmax for Norethindrone(Maximum Observed Concentration of Drug Substance in Plasma) — 10.08; 9.90 ng/mL
Healthy
Primary: Cmax of Norethindrone (Maximum Observed Concentration of Drug Substance in Plasma) — 6.54; 6.06 ng/mL
Healthy
Primary: Maximum Plasma Morphine Concentration — 5.23; 4.15 ng/mL
Bioequivalence
Primary: Androxal Cmax Formulation A — 0.999; 1.67 ng/mL
Relapsing Remitting Multiple Sclerosis
Primary: The Bioequivalent (BE) Comparison of AUC0-inf of Monomethyl Fumarate (MMF) Between Treatments — 2984; 3116 ng*hr/mL
Healthy
Primary: Maximum Plasma Morphine Concentration — 4.60; 4.29 ng/mL
Vulvovaginal Atrophy · Vasomotor Symptoms
Primary: To Determine the Steady State Concentration (Css) for Estradiol — 14.4; 29.7; 33.8 pg/mL
Post-Menopausal Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine BMD at Month 6 — 9.2; 9.0 percent change — p=0.84
Tumor
Primary: Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-∞) of Sitravatinib — 2524.7; 2892.6 h*ng/mL
Postmenopausal Women With Osteoporosis
Primary: Percentage Change in Lumbar Spine BMD (Bone Mineral Density) — 1.698; 1.440 Percent change
Hypogonadism
Primary: The Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Testosterone Enanthate Formulations at 6 Weeks — 150445.2; 70955.7; 278657.9…
Healthy Volunteer
Primary: Maximum Observed Drug Concentration (Cmax) of Denosumab — 12.7; 11.8 μg/mL
Healthy Volunteers
Primary: Maximum Observed Concentration (Cmax) of GDC-0134. — 5.56; 4.45; 2.66; 2.68 uM
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of GDC-9545 — 126; 129; 102 nanograms per millilitre (ng/mL)
Female Sexual Dysfunction
Primary: Bioavailability (AUC0-t) of Total Testosterone Through Pharmacokinetic (PK) Profiles — 223.981; 328.002; 834.391; 553.325 ng*h/dL
Healthy
Primary: AUC0-t — 38.3; 40.2; 43.6; 70.4 ng*h/mL
Phase 1 Pharmacodynamic Study
Primary: Pharmacodynamic Effect of Oral Calcitonin — 37.5; 100; 41.2; 44.4 percentage of time-matched placebo respo
Parkinson
Primary: Cmax - Maximum Observed Plasma Concentration — 635.0; 238.2 ng/mL
Healthy
Primary: AUC0-tz — 300; 310; 306 ng*h/mL — p=<0.0001
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 participants
Pain
Primary: Area Under the Curve From Time Zero to Last Sampling Time [AUC(0-t)] — 15.212; 14.698 hours*microgram/millilitre (h*μg/mL)
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 0.61; 0.54 ng/mL
Atrophy
Primary: Percentage of Subjects Identified as Responders — 36.8; 32.0; 0.8 percentage of responders
Osteoporosis
Primary: Part 1: Urinary Excretion of Alendronate — 133.6; 132.2 μg
Healthy
Primary: Cmax of Drospirenone(Maximum Observed Concentration of Drug Substance in Plasma) — 52.77; 53.65 ng/mL
Postmenopausal Symptoms
Primary: AUC (Hour*ng/mL) Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg — 86.95; 78.80; 38.90 Hour*ng/mL
Type 2 Diabetes Mellitus
Primary: Saxagliptin Maximum Observed Concentrations (Cmax) — 26.2; 25.5 ng/mL — p=0.4950